Abstract. Lipid rafts, specialized domains in cell membranes, function as physical platforms for various molecules to coordinate a variety of signal transduction processes. Flotillin-2 (FLOT2), a marker of lipid rafts, is involved in the progression of cancer, yet the precise mechanism remains unclear. In the present study, we examined the effect of FLOT2 on cell proliferation and found that silencing endogenous FLOT2 with shRNAs inhibited proliferation of breast cancer cells. Furthermore, the antiproliferative effect of silencing FLOT2 on breast cancer cells was associated with upregulation of cyclin-dependent kinase (CDK) inhibitors p21Cip1 and p27Kip1. Moreover, we further demonstrated that the silencing of FLOT2 enhanced the transcriptional activity of FOXO factors by decreasing its phosphorylation through inhibiting the PI3K/Akt signaling pathway. Taken together, our results provide the first demonstration of a novel mechanism by which FLOT2 induces proliferation of breast cancer cells, and our findings suggest that FLOT2 plays an important role in oncogenesis of breast cancer and thereby may be a potential target for human breast cancer treatment.

Introduction

Breast cancer is the most common malignancy in females worldwide (1,2). Despite great advances in diagnosis and appropriate systemic therapy, the mortality of breast cancer remains high, accounting for 14% of the total cancer-related deaths (3). Identifying key molecules contributing to the malignant properties of breast cancer cells is essential for future development of new and effective anti-breast cancer approaches.

Materials and methods

Cell lines. Breast cancer MCF-7 and MDA-MB-231 cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA).

Vectors and gene transduction. Expression of FLOT2 was stably knocked down in MCF-7 and MDA-MB-231 cells using the pSUPER-retroviral vector and the oligonucleotides for FLOT2 as previously described for HeLa cells (14). Recombinant retroviral vectors were produced by transient
cotransfection as previously described (15). Viral infection was performed serially, and stable cell lines expressing FLOT2-RNAs were selected with 0.5 µg/ml puromycin 48 h after infection. After a 10-day selection, whole cell lysates were fractionated on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to examine the level of FLOT2 protein.

Western blot analysis. Western blotting was performed according to standard methods as previously described (16), using anti-p-Akt (ser473), anti-Akt, anti-p-Rb (ser608), anti-Rb, anti-p-FOXO1 (ser256), anti-FOXO1, anti-FOXO3a (ser253), anti-FOXO3a, anti-p-FOXO4 (Ser193), anti-FOXO4, anti-cyclin A, anti-CDK4, anti-CDK6, anti-p21^Cip1^ and anti-p27^Kip1^ (Cell Signaling Technology, Danvers, MA, USA); and anti-FLOT2 and anti-α-tubulin (Sigma-Aldrich, St. Louis, MO, USA).

Real-time PCR. Total RNA from cultured cells was extracted using the RNeasy kit (Qiagen, Crawley, UK). Each cDNA template was made from total RNA with a reverse transcriptase kit according to the manufacturer's instructions (Invitrogen). Amplification reactions were performed using the SYBR Premix Ex Taq™ (Takara Shuzo, Kyoto, Japan) in a 25 µl volume. The following cycling parameters were used: 30 sec at 95°C for initial denaturing, 5 sec at 95°C for denaturing and 30 sec at 60°C for annealing and extension for a total of 40 cycles. The fold-change in mRNA was calculated by the \(2^{-\Delta\Delta Ct}\) method. All samples were normalized to GAPDH. The primer sequences used were: p21^Cip1^-up, 5'-CGATGCAACCTCCTCAACGA-3' and p21^Cip1^-dn, 5'-TCGCAGACCCTCCATCCA-3'; p27^Kip1^-up, 5'-TGCAACCGACGATTCTTACTCAA-3' and p27^Kip1^-dn, 5'-CAACGCAGTTGATGTATCCTGATACCAAGGA-3' and GAPDH-up, 5'-TCCACCACCTTCTTGCTGTA-3'.

3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. MTT assay was performed as previously described (17). Briefly, cells were seeded in 96-well flat-bottom plates at a density of 0.2x10^4 cells/well. At each time point, the cell viability was determined by MTT assay. Data points are presented as means ± SD of triplicate experiments. FLOT2, flotillin-2.

Flow cytometry. Cells were harvested, washed with cold phosphate-buffered saline (PBS) and processed for cell cycle analysis using flow cytometry. Briefly, the cells were fixed in 75% ethanol and stored at -20°C for later analysis. The fixed cells were centrifuged at 1,000 rpm and washed with cold PBS twice. RNase A (20 µg/ml final concentration) and propidium iodide (PI) staining solution (50 µg/ml final concentration) was added to the cells and incubated for 30 min at 37°C in the dark. Fifty thousand cells were analyzed using a FACSCalibur instrument (Becton-Dickinson, San Jose, CA, USA).

Statistical analysis. The data given in the text are expressed as means ± standard deviations (SD). Comparisons between groups for statistical significance were carried out with a two-tailed Student's t-test. In all cases, p<0.05 was considered to indicate a statistically significant result.

Results

Downregulation of FLOT2 inhibits the proliferation of breast cancer cells. To evaluate the biological function of FLOT2 in breast cancer, we constructed FLOT2-knockdown cell models using two FLOT2-specific shRNAs. As shown in Fig. 1, both shRNAs effectively knocked down the expression of endogenous FLOT2 protein in both the MCF-7 and MDA-MB-231 cells. An MTT assay showed that depletion of FLOT2 expression caused a significant reduction in viability of both MCF-7 and MDA-MB-231 breast cancer cell lines (Fig. 2), and...
these results were further confirmed by a colony formation assay (Fig. 3). These data suggest that FLOT2 may be involved in promoting the proliferation of breast cancer cells.

Figure 3. Silencing of endogenous FLOT2 inhibits cell growth as determined by colony formation assay. (A) Representative images of the crystal violet-stained cells. (B) Quantification of crystal violet-stained cells. Error bars represent SD calculated from three independent experiments. *p<0.05; significant differences compared with the control. FLOT2, flotillin-2.

Silencing of FLOT2 results in the G1-S phase cell cycle arrest of breast cancer cells. To investigate the mechanism that mediates the proliferation-promoting function of FLOT2, a BrdUrd incorporation assay was performed. As shown in Fig. 4, the silencing of FLOT2 in the MCF-7 and MDA-MB-231 cells markedly decreased the percentages of cells with incorporated BrdUrd. Flow cytometric analysis showed that downregulation of FLOT2 significantly increased the percentage of cells in the G0/G1 peak but decreased the percentage of cells in the S peak (Fig. 5). These results suggest...
that the silencing of FLOT2 induces G1-S phase arrest of breast cancer cells.

**Silencing of FLOT2 upregulates cell cycle inhibitors p21^Cip1 and p27^Kip1 in breast cancer cells.** The observed correlation of
The present study demonstrated that knockdown of endogenous FLOT2, a lipid raft specific protein, inhibited the proliferation of breast cancer cells. We showed that silencing of FLOT2 using RNAi resulted in suppression of Akt phosphorylation and subsequent activation of FOXOs, which led to the upregulation of CDK inhibitors p21Cip1 and p27Kip1. These findings provide new insights into the potential role of the upregulation of FLOT2 in promoting oncogenesis and progression of breast cancer.

Oncogenesis is a complex multi-step process, characterized by uncontrolled cell growth and tumor formation. During oncogenesis cells proliferate in a progressive, deregulated manner. Uncontrolled cell growth is associated with various alterations in genes or proteins related to regulation of proliferation, cell death and genetic stability, such as tumor-suppressor genes, oncogenes, growth factors and cell adhesion molecules (23). Thus, identification of genes and their products involved in the molecular events leading to oncogenesis is the key to the development of effective therapeutic strategies.

A correlation of FLOT2 with cancer development and progression has recently been demonstrated by studies from several groups, in which FLOT2 was found to be expressed at high levels in various types of human cancers, including head and neck cancer, melanoma, gastric cancer, nasopharyngeal carcinoma and breast cancer (8-13). Consistent with these clinical findings, at the cellular level we found that depletion of FLOT2 suppressed the proliferation of breast cancer cells, a key biological event essential for cancer development and progression. The experiments on the effects of FLOT2 depletion on cell viability, colony-formation ability and BrdUrd incorporation confirmed that FLOT2 is a proliferation promoter. Further experiments showed that silencing of FLOT2 in breast cancer cells enhanced G1-S phase arrest. Such a connection between FLOT2 and G1/S phase transition was shown to be mechanistically mediated by the cell cycle inhibitors p21Cip1 and p27Kip1, which the present study demonstrated to be upregulated by knocking down FLOT2 in the breast cancer cells.

FOXO proteins are a family of transcription factors that play important roles in regulating the expression of genes involved in a variety of biological processes, such as proliferation, differentiation, stress response and cellular apoptosis (24,25). It has been demonstrated that FOXO proteins act as tumor suppressors as evidenced by its transcriptional induction of CDK inhibitors, including p21Cip1, p27Kip1 and p57Kip2. It has been demonstrated that phosphorylation of FOXOs by Akt leads to FOXO nuclear/cytoplasmic translocation and subsequent degradation via the ubiquitin-proteasome system (26,27). In the present study, decreased phosphorylation, and subsequent increased transcriptional activity, of FOXO factors (FOXO1, FOXO3a and FOXO4), which are known activators for p21Cip1 and p27Kip1 transcription, was found when FLOT2 expression was depleted and such an effect was likely to be mediated by suppression of Akt phosphorylation.

In summary, our finding that knockdown of FLOT2, a marker of lipid rafts, inhibited the proliferation of breast cancer cells through modulation of the Akt/FOXO/p21/p27 pathway illustrates a new mode of action in the molecular mechanism.
underlying the oncogenesis of breast cancer. Understanding the precise role played by FLOT2 in breast cancer progression will not only increase our knowledge of the biology of breast cancer but may also enable development of a novel therapeutic strategy via suppression of FLOT2.

Acknowledgements

The present study was supported by a grant from the National Natural Science Foundation of China (no. 81101682), a Science and Technology Planning Project of Guangzhou Municipal Health Bureau (no. 201102A213045), and a Ph.D. Start-up Fund of Guangzhou Women and Children’s Medical Center (no. 201012).

References